Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

1. Global burden of cardiovascular disease - 2. Heart disease in varied populations - 3. Ethics in cardiovascular medicine - 4. Clinical decision making in cardiology - 5. Measurement and improvement of quality of cardiovascular care - 6. Design and conduct of clinical trials - 7. Principles of cardiovascular molecular biology and genetics - 8. Inherited causes of cardiovascular disease - 9. Genetics of cardiac arrhythmias - 10. Principles of drug therapy - 11. Cardiovascular regeneration and tissue engineering - 12. The history and physical examination - 13. Electrocardiography - 14. Exercice stress testing - 15. Echocardiography - 16. The chest radiograph in cardiovascular disease - 17. Nuclear cardiology - 18. Cardiovascular magnetic resonance imaging - 19. Cardiac computed tomography - 20. Cardiac catherization - 21. Coronary arteriography - 22. Intravascular ultrasound imaging - 23. Molecular imaging in cardiovascular disease - 24. Mechanisms of cardiac contraction and relaxation - 25. Pathophysiology of heart failure - 26. Clinical assessment of heart failure - 27. Diagnosis and management of acute heart failure syndromes - 28. Management of heart failure patients with reduced ejection fraction - 29. Devices for monitoring and managing heart failure - 30. Heart failure with normal ejection fraction - 31. Surgical management of heart failure - 32. Assisted circulation in the treatment of heart failure - 33. Emerging therapies and strategies in the treatment of heart failure - 34. Care of patients with end-stage heart disease - 35. Genesis of cardiac arrhythmias - 36. Diagnosis of cardiac arrhythmias - 37. Therapy for cardiac arrhythmias - 38. Pacemakers and implantable cardioverter-defibrillators - 39. Specific arrhythmias : diagnosis and treatment - 40. Atrial fibrillation : clinical features, mechanisms and management - 41. Cardiac arrest and sudden cardiac death - 42. Hypotension and syncope - 43. The vascular biology of atherosclerosis - 44. Risk markers for atherothrombotic disease - 45. Systematic hypertension : mechanisms and diagnosis- 46. Systematic hypertension : therapy - 47. Lipoprotein disorders and cardiovascular disease - 48. Nutrition and cardiovascular disease - 49. Primary and secondary prevention of coronary heart disease - 50. Exercice-based, comprehensive cardiac rehabilitation - 51. Complementary and alternative approaches to management of patients with heart disease - 52. Coronary blood flow and myocardial ischemia - 53. Approach to the patient with chest pain - 54. ST-segment elevation myocardial infarction : pathology, pathophysiology and clinical features - 55. ST-segment elevation myocardial infarction : management - 56. Unstable angina and non-ST elevation myocardial infarction - 57. Stable ischemic heart disease - 58. Percutaneous coronary intervention - 59. Percutaneous therapies for structural heart disease in adults - 60. Diseases of the aorta - 61. Peripheral artery diseases - 62. Prevention and management of stroke - 63. Endovascular treatment of noncoronary obstructive vascular disease - 64. Diabetes and the cardiovascular system - 65. Congenital heart disease - 66. Valvular heart disease - 67. Infective endocarditis - 67. The dilated, restrictive and infiltrative cardiomyopathies - 69. Hypertrophic cardiomyopathy - 70. Myocarditis - 71. Chagas' disease - 72. Cardiovascular abnormalities in HIV-infected individuals - 73. Toxins and the heart - 74. Primary tumors of the heart - 75. Pericardial diseases - 76. Traumatic heart disease - 77. Pulmonary embolism - 78. Pulmonary hypertension - 79. Sleep apnea and cardiovascular disease - 80. Cardiovascular disease in the elderly - 81. Cardiovascular disease in women - 82. Pregnancy and heart disease - 83. Exercise and sports cardiology - 84. Medical management of the patient undergoing cardiac surgery - 85. Anesthesia and noncardiac surgery in patients with heart disease - 86. Endocrine disorders andcardiovascular disease - 87. Hemostatis, thrombosis, fibrinolysis and cardiovascular disease - 88. Rheumatic fever - 89. Rheumatic diseases and the cardiovascular system - 90. The cancer patient and cardiovascular disease - 91. Psychiatric and behavioral aspects of cardiovascular disease - 92. Neurologic disorders and cardiovascular disease - 93. Interface between renal disease and cardiovascular illness - 94. Cardiovascular manifestations of autonomic disorders

Heart Diseases. --- Cardiovascular Diseases. --- Heart --- Cardiology. --- Coeur --- Cardiologie --- Diseases --- Maladies --- Diseases. --- Cardiovascular Disease --- Disease, Cardiovascular --- Diseases, Cardiovascular --- Cardiology --- Cardiac Diseases --- Cardiac Disease --- Disease, Cardiac --- Disease, Heart --- Diseases, Cardiac --- Diseases, Heart --- Heart Disease --- Cardiovascular Diseases --- Heart Diseases --- Cardiac diseases --- Heart diseases --- Internal medicine --- Cardiac Disorders --- Heart Disorders --- Cardiac Disorder --- Heart Disorder --- E-books --- Adverse Cardiac Event --- Cardiac Events --- Major Adverse Cardiac Events --- Adverse Cardiac Events --- Cardiac Event --- Cardiac Event, Adverse --- Cardiac Events, Adverse --- Event, Cardiac

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Spanish language --- English. --- Medical Spanish --- Castilian language --- Romance languages

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. There are numerous literature resources available to pharmaceutical scientists to educate and provide guidance toward formulations development with poorly water-soluble drugs; however, a single, comprehensive reference is lacking. Furthermore, without access to a vast journal library, the detailed methods used to implement these approaches are not available. The objective of this volume is therefore to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules.

Pharmacology. Therapy --- farmacologie --- Drug Compounding. --- Solubility. --- Biological Availability. --- Chemistry, Pharmaceutical --- Chemical Phenomena. --- methods. --- Drug Compounding --- Solubility --- Biological Availability